Evidence map›Paper›PMID 34898564›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Canadian Consensus Recommendations on the Management of

Parneet K Cheema, Shantanu O Banerji, Normand Blais, Quincy S-C Chu, Patrice Desmeules, Rosalyn A Juergens, Natasha B Leighl, Brandon S Sheffield, Paul F Wheatley-Price, Barbara L Melosky

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Parneet K CheemaMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Shantanu O BanerjiCancerCare Manitoba Research Institute, Department of Medical Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.ORCID 0000-0002-7531-1378
Normand BlaisDepartment of Medicine, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC H2X 3E4, Canada.ORCID 0000-0003-2698-4362
Quincy S-C ChuCross Cancer Institute, Alberta Health Services, Edmonton, AB T6G 1Z2, Canada.
Patrice DesmeulesService d'Anatomopathologie et de Cytologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, QC G1V 0A6, Canada.
Rosalyn A JuergensDepartment of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
Natasha B LeighlPrincess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Brandon S SheffieldDepartment of Laboratory Medicine, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Paul F Wheatley-PriceDepartment of Medicine, The Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Barbara L MeloskyDepartment of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC V5Z 4E6, Canada.
Alberta Health Services · CACancerCare Manitoba · CACentre Hospitalier de l’Université de Montréal · CAInstitut universitaire de cardiologie et de pneumologie de Québec · CAJuravinski Cancer Centre · CAUniversity Health Network · CAUniversity of Ottawa · CAUniversity of Toronto · CAWilliam Osler Health System · CA

Funding

EMD Serono N/A
6 · The paper itself

Abstract

In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatments. These variations, together with the emergence of several novel mesenchymal-epithelial transition (

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCanadaConsensusHumansProtein Kinase InhibitorsProtein Kinase InhibitorsEGFR resistanceMET amplificationMET exon 14 skipping mutationsMET inhibitorsnon-small cell lung cancer

Identifiers

PMID34898564
PMCPMC8628757
OpenAlexW3213091002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.